Andrew Goodall
Geen lopende functies
Vermogen: 1 M $ op 30-04-2024
Profiel
Andrew Ernest Goodall served as a Non-Executive Director at Memphasys Ltd.
from 2012 to 2023.
He also held the same position at PrIME Biologics Pte Ltd.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
MEMPHASYS LTD
13.17% | 29-11-2023 | 180 149 529 ( 13.17% ) | 1 M $ | 30-04-2024 |
Eerdere bekende functies van Andrew Goodall
| Bedrijven | Functie | Einde |
|---|---|---|
| MEMPHASYS | Directeur/Bestuurslid | 30-11-2023 |
PrIME Biologics Pte Ltd.
 PrIME Biologics Pte Ltd. BiotechnologyHealth Technology PrIME Biologics Pte Ltd. develops disposable therapeutic plasma manufacturing process. Its process doubles product yields while increasing product safety and removing viruses, bacteria, endotoxins, and prions. The firm’s process reduces the time it takes to produce multiple plasma products from days to hours. The company is headquartered in Singapore. | Directeur/Bestuurslid | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| MEMPHASYS | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
PrIME Biologics Pte Ltd.
PrIME Biologics Pte Ltd. BiotechnologyHealth Technology PrIME Biologics Pte Ltd. develops disposable therapeutic plasma manufacturing process. Its process doubles product yields while increasing product safety and removing viruses, bacteria, endotoxins, and prions. The firm’s process reduces the time it takes to produce multiple plasma products from days to hours. The company is headquartered in Singapore. | Health Technology |